Loading...
A Peer-reviewed, open access journal sponsored by TMR publishing group
Editor-in-Chief: Dan Chen, PhD. Prof.
ISSN 2624-3075
7Drug Combination Therapy is an international peer-reviewed, open access journal sponsored by TMR publishing group. DCT aims to publish unbiased original articles, reviews, letters, news and comment in all areas of drug combination therapy. DCT is dedicated to report the latest advancements and the research done in drug combination along with all the relevant fields, including but not limited to prescription compatibility studies, disassembled formulae studies, drug compatibility synergetic/antergic mechanisms, drug incompatibility/adverse reactions, combination therapy for specific populations, integrated pharmacology studies, system/network pharmacology, big data analysis, systematic evaluation/meta-analysis, omics research, natural products chemistry, pharmaceutical analysis, etc. In order to focus on breakthrough research in a field, DCT insist on publishing special issues around a topic related to drug combination therapy. DCT has been included in CAS, doaj, EuroPub, Google Scholar, CNKI Scholar, VIP Data, Superstar Journals Database and Traditional Medicine Research Data Expanded. ... More

Topics More

Call for PaperMore

Current Issue     05 February 2020, Volume 2 Issue 1 Previous Issue   
For Selected: View Abstracts Toggle Thumbnails

Orginal Article
Jianpi Bushen Recipe affects epithelial-mesenchymal transition in hepatocellular carcinoma through TGF-β and Twist
Hong-Jie Liu, You-Ying Lai, Zhi-Fen Han, Jian-Jie Chen, Xin-Wen Ma
7Drug Combination Therapy. 2020, 2 (1): 1-6.   https://doi.org/10.12032/DCT201905004
Abstract ( 59 )     PDF (1055KB) ( 44 )  
Backgroud: To explore the effects of Jianpi Bushen Recipe on the epithelial-mesenchymal transition (EMT) of nude mice with transplanted human liver cancer SK-HEP-1 cells. Methods: To establish models with transplanted liver cancer cells, nude mice were divided randomly into three groups: blank group, traditional Chinese medicine (TCM) group and control group. They were given normal saline, Jianpi Bushen Recipe and solafeni through administration by gavage for four weeks. The expression of TGF-β and twist mRNA were detected by real-time PCR. The expression of E-cadherin was detected by Western blot. Results: Compared with the blank group, the expression of transforming growth factor-β (TGF-β) mRNA and twist mRNA in the TCM group and the control group decreased significantly (P < 0.05). There was no significant difference between the two groups (P > 0.05). The expression of E-cadherin protein in TCM group and control group increased significantly (P < 0.01). There was no significant difference between the two groups (P > 0.05). Conclusion: Jianpi Bushen Recipe can inhibit the EMT of liver cancer SK-HEP-1 cells in vivo by down-regulating the expression of TGF-β/twist signaling and indirectly up-regulating E-cadherin expression in transplanted liver cancer tissue, indicating the potential of Jianpi Bushen Recipe to inhibit invasion and metastasis of liver cancer.
Review
A Meta-analysis of Dachaihu Decoction combined with western medicine in the treatment of acute pancreatitis with the TCM syndrome of liver qi depression and liver-gallbladder dampness-heat
Kai-Bin Sun, Xin-Yu Zhang, Rong Sun
7Drug Combination Therapy. 2020, 2 (1): 7-15.   https://doi.org/10.12032/DCT201905003
Abstract ( 69 )     PDF (1684KB) ( 63 )  
Backgroud: To evaluate the clinical efficacy and safety of Dachaihu Decoction in the treatment of acute pancreatitis (AP) with the traditional Chinese medicine (TCM) syndrome of liver qi depression and liver-gallbladder dampness-heat. Methods: We searched randomized controlled trials of Dachaihu Decoction in the treatment of AP with the TCM syndrome of liver qi depression and liver-gallbladder dampness-heat from databases in CNKI, WanFang, VIP, Embase, PubMed, and Cochrane Library (from established to August 2019). All the retrieved documents were imported into the Noteexpress software for screening and management, and the included documents were evaluated for quality and data extracted. Statistical analysis was performed with RevMan (version 5.3). Results: A total of 132 articles were retrieved and 8 studies were included to analysis, including 679 patients. Quality evaluation of included studies suggested that the quality of the literatures is generally not high. Meta-analysis showed that the total clinical effective rate of AP was higher in the treatment group than in the control group [OR = 5.00, 95% CI (2.86, 8.73)], and the difference was statistically significant (P < 0.00001). The patient’s abdominal pain relief time [MD = -0.57, 95% CI (-0.86, -0.27), P = 0.0002], bloating relief time [MD = -0.71, 95% CI (-1.05, -0.37), P = 0.04], time of serum amylase returning to normal [MD = -1.00, 95% CI (-1.60, -0.40), P = 0.001] and time of urinary amylase returning to normal [MD = -1.62, 95% CI (-2.88, -0.37), P = 0.01] all lower than the control group. But there was no statistically significant difference between the treatment group and the control group at the first defecation time [MD= -0.86, 95% CI (-1.75, -0.03), P = 0.06]. The patient’s serum TNF-α levels on the 3rd [MD = -28.53, 95% CI (-49.57, -7.49), P = 0.008] and 7th day [MD = -26.13, 95% CI (-49.76, -2.50), P = 0.03] in the treatment group were statistically lower in the treatment group than in the control group. Similarly, the patient’s serum IL-6 levels on the 3rd [MD= -6.62, 95% CI (-12.49, -0.75), P = 0.03] and 7th day [MD = -11.98, 95% CI (-22.25, -1.71), P = 0.02] were also statistically lower in the treatment group than in the control group. No serious complications or adverse reactions were observed. Conclusion: Dachaihu Decoction combined with western medicine in the treatment of AP with the TCM syndrome of liver qi depression and liver-gallbladder dampness-heat can improve clinical efficacy compared with western medicine alone. In addition, the combination therapy method is safe and can be used for syndrome differentiation of AP patients in the clinic. 
Analysis of compatibility rules and mechanisms of traditional Chinese medicine for preventing and treating postoperative recurrence of bladder cancer
Xin-Zhe Zhao, Yao Yang, Ying Chen, Li-Hui Zhang, Guo-Wei Zhang
7Drug Combination Therapy. 2020, 2 (1): 16-24.   https://doi.org/10.12032/DCT202001001
Abstract ( 41 )     PDF (1310KB) ( 45 )  

Backgroud: Summarize the formula rule of traditional Chinese medicine for preventing and treating bladder cancer recurrence after operation and explore the molecular mechanism of core medicines. Methods: Literatures collected from CNKI, Wanfang Med Online, CMJD, PUBMED and Elsiver databases were as prescription sources, and association rules and complex system entropy clustering analysis were carried out using the Traditional Chinese Medicine Inheritance Support System (TCMISSV2.5). BATMAN-TCM online analysis tool was used to construct target-pathway-disease correlation map to reveal the potential mechanism of action. Results: A total of 122 prescriptions were eligible for data analysis. The high-frequency traditional Chinese medicines are Poria, Radix et Rhizoma Rhei, Radix Astragali, Herba Hedyotidis Diffusae and Rhizoma Atractylodis Macrocephalae. The high-frequency drug pairs are Rhizoma Atractylodis Macrocephalae/Poria, Poria/Rhizoma Alismatis, Radix Astragali/Rhizoma Atractylodis Macrocephalaeand and Herba Hedyotidis Diffusae/Herba Scutellariae Darbatae.. There are 5 groups of drug pairs with high correlation strength. Cluster analysis shows 6 core drug combinations and 3 new prescriptions. In clinical practice, the core compatibility of traditional Chinese medicines for preventing postoperative recurrence of bladder cancer is Poria, Radix Astragali and Herba Hedyotidis Diffusae. The possible signaling pathways are the neuroactive ligand receptor interaction signaling pathway and calcium signaling pathway. Conclusion: Prevention and treatment of postoperative recurrence of bladder cancer mainly use medicines with effects of eliminating dampness and diuresis for removing edema, heat-clearing and detoxifying, and qi-invigorating. The potential mechanism of the compatibility of core drugs may be realized by interfering with the signal pathway of neuroactive ligand receptor interaction and calcium signal pathway.

CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer
Xue Yang
7Drug Combination Therapy. 2020, 2 (1): 25-33.   https://doi.org/10.12032/DCT202001002
Abstract ( 65 )     PDF (1170KB) ( 159 )  
Endocrine therapy (ET) is the therapy backbone of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. However, there are about 20% HR positive patients with no response to ET due to primary or acquired ET resistance. In this background, many agents have been studied to overcome ET resistance and of which the important agents are cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The prognosis of advanced breast cancer has been improved by combing ET with CDK4/6 inhibitors. In this review, we mainly focused on the CDK4/6 inhibitors in the treatment of HR-positive, HER2-negative advanced breast cancer and discussed the action mechanisms of CDK4/6 inhibitors alone or combined with ET. We also summarized several molecular features that would predict response or resistance to CDK4/6 inhibitors. In addition, we put forward possible strategies to overcome CDK4/6 inhibitor resistance according to the latest research.
Report
Traditional Chinese medicine combined with low-dose glucocorticoid for treating nephrotic syndrome: A case report
Shu-Ting Huang, Si-Chao Ding, Gan-Feng Xu
7Drug Combination Therapy. 2020, 2 (1): 34-44.   https://doi.org/10.12032/DCT201905002
Abstract ( 66 )     PDF (1291KB) ( 39 )  
Nephrotic syndrome (NS) is a common refractory clinical disease that can develop into end-stage renal disease (ESRD) if cannot be controlled. At present, in Western medicine, glucocorticoid or immunosuppressant drugs with heavy dose and long course are used for the therapy of NS. There are still few reports on the combined treatment of traditional Chinese medicine and low-dose glucocorticoid for NS. Here, we reported a case of a 48-year-old man diagnosed with NS, accompanied by severe pulmonary infection, abundant proteinuria, and pleural effusion. Integrated traditional Chinese and Western medicine was used as the therapeutic regimen of this patient. Traditional Chinese medicine (TCM) mainly focused on invigorating spleen and kidney, promoting blood circulation, removing blood stasis and promoting diuresis, and Chinese patent medicines or TCM immunosuppressants were given to consolidate the treatment. In Western medicine, small dose and short course glucocorticoids combined with symptomatic treatment were adopted. Delightfully,  proteinuria subsided after 5 months treatment with integrated TCM and Western medicine and all laboratory reports were negative after 10 months, which has been normal so far (July 2019). This case report indicates that the combination of TCM and low-dose glucocorticoid is effective in curing NS, with low recurrence rate and few side effects.

2019-nCoV

Annual Advances

TMR Data ExpandedMore

ScientistsMore

NoticesMore

Online FirstMore
    Please wait a minute...
  • Study on the therapeutic effect of external application of ShouNian Powder combined with acupuncture at Zhitong acupoint on ICBN syndrome after breast cancer operation 
    ...
    Objective: To explore the clinical effect of external application of ShouNian Powder combined with acupuncture at Zhitong acupoint in the treatment of intercostobrachial nerve syndrome (ICBNs) after breast cancer operation. Methods: A total of 80 patients with ICBNs who underwent modified radical mastectomy in our hospital from July 2014 to July 2016 were collected and divided into control group and study group according to the different treatment methods of ICBNs. 40 patients in the control group were treated with symptomatic analgesia and 40 patients in the study group were treated with external application of ShouNian Powder combined with acupuncture at Zhitong acupoint to compare and analyze the pain relief, quality of life and analgesic recurrence rate of ICBNs between the two groups. Results: Compared with the control group, the pain relief rate of ICBNs in the study group was higher. The patient satisfaction and long-term quality of life in the study group were better than those in the control group. However, there was no significant difference in postoperative pain recurrence rate. Conclusion: External application of ShouNian Powder combined with acupuncture at Zhitong acupoint can effectively relieve pain and improve quality of life for patients with ICBNs after breast cancer operation, which has a certain popularizing significance in clinical practice....
    Ning Mao, Yin-Hai Dai, Zhi-Yong Shao, Mao Wang, Jun-Yi Bai, Qian-Qian Liang